A VEGFR2–MICA bispecific antibody activates tumor-infiltrating lymphocytes and exhibits potent anti-tumor efficacy in mice

Prognostic value of serum levels of soluble MICA (sMICA) in patients with prostate cancer

(2018) Y Liu et al.   BRITISH JOURNAL OF BIOMEDICAL SCIENCE

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa

(2018) Kabir A. Khan et al.   Nature Reviews Clinical Oncology

Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity

(2018) Lucas Ferrari de Andrade et al.   SCIENCE

Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy

(2017) Keehoon Jung et al.   JOURNAL OF CLINICAL INVESTIGATION

A Novel Fusion Antibody Exhibits Antiangiogenic Activity and Stimulates NK Cell-mediated Immune Surveillance Through Fused NKG2D Ligand

(2017) Desmond O. Acheampong et al.   JOURNAL OF IMMUNOTHERAPY

A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma

(2016) Tong Wang et al.   CANCER LETTERS

Antiangiogenic therapy in oncology: current status and future directions

(2016) Gordon C Jayson et al.   LANCET

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

(2016) Jeffrey J. Wallin et al.   Nature Communications

Regulation of NKG2D+CD8+ T-cell-mediated antitumor immune surveillance: Identification of a novel CD28 activation-mediated, STAT3 phosphorylation-dependent mechanism

(2016) Jiemiao Hu et al.   OncoImmunology

Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy

(2015) Lee B. Rivera et al.   Cell Reports

High Expression of MICA in Human Kidney Cancer Tissue and Renal Cell Carcinoma Lines

(2014) Hong-Ying Jia et al.   Asian Pacific Journal of Cancer Prevention

Generation and characterization of a novel human IgG1 antibody against vascular endothelial growth factor receptor 2

(2014) Wei Xie et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cutting Edge: The Metalloproteinase ADAM17/TNF- -Converting Enzyme Regulates Proteolytic Shedding of the MHC Class I-Related Chain B Protein

(2014) P. Boutet et al.   JOURNAL OF IMMUNOLOGY

IFNγ-responsiveness of endothelial cells leads to efficient angiostasis in tumours involving down-regulation of Dll4

(2014) Jingjing Deng et al.   JOURNAL OF PATHOLOGY

Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

(2014) F. S. Hodi et al.   Cancer Immunology Research

Regulation of Ligands for the NKG2D Activating Receptor

(2013) David H. Raulet et al.   Annual Review of Immunology

Phage-derived fully human antibody scFv fragment directed against human vascular endothelial growth factor receptor 2 blocked its interaction with VEGF

(2012) Juan Zhang et al.   BIOTECHNOLOGY PROGRESS

Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding

(2012) Leticia Huergo-Zapico et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target

(2012) B. Sitohy et al.   CANCER RESEARCH

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

(2012) Y. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor angiogenesis: molecular pathways and therapeutic targets

(2011) Sara M Weis et al.   NATURE MEDICINE

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

(2010) R. K. Shrimali et al.   CANCER RESEARCH

NK cell-mediated killing of target cells triggers robust antigen-specific T cell-mediated and humoral responses

(2009) P. Krebs et al.   BLOOD

Responsiveness of Stromal Fibroblasts to IFN-  Blocks Tumor Growth via Angiostasis

(2009) Y. Lu et al.   JOURNAL OF IMMUNOLOGY

Tumor-Associated MICA Is Shed by ADAM Proteases

(2008) I. Waldhauer et al.   CANCER RESEARCH

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma

(2008) M. Jinushi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA